BioAlliance Pharma annonce :
Obtention du statut « médicament orphelin » pour clonidine LauriadTMen Europe
****
BioAlliance Pharma announces:
Grant of « orphan designation » for clonidine LauriadTM in Europe
Paris, November 2, 2011 – BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan oncology products, today announced that clonidine LauriadTM has been granted orphan designation by the European Commission in the prevention of radiotherapy-induced oral mucositis in patients with head and neck cancer.
The entire press release is available by clicking on the link above.
Best regards,
Anne-Sophie Cosquéric Attachée de presse Tel: + 33 (0) 1 42 68 86 41 Mob : + 33 (0) 6 48 82 18 94 ALIZE RP 33, rue de Surène 75008 Paris Fax: + 33 (0) 1 42 68 06 51
Télécharger le communiqué
!:!iframe http://www.nextnews.fr/upload/fr/nextnews%5Fbioalliance%5Fpharma%5Fobtention%5Fdu%5Fstatut%5F%AB%5Fmedicament%5Forphelin%5F%BB%5Fpour%5Fclonidine%5Flauriad%99en%5Feurope%5F57097%2EPDF!:!
En partenariat avec NextNews
Partager : |
|
Tweet |
|
|
|